drugset / Trial / NCT00134654
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
Phase 2
Completed
48 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabEmerson Hospital, Concord, MA · collabLowell General Hospital · collabMassachusetts General Hospital · collabSaint Anne's Hospital · collabSouth Shore Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see if Premarin is useful against androgen-independent prostate cancer and to help understand how drugs such as Premarin may work.
Timeline
- Start
- 2003-03
- Primary completion
- 2005-07
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | conjugated estrogens | Other / unclassified | 1.25 mg | — |